Atlas Trials

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Clinical trial NCT00715364 · WITHDRAWN

Trial details

NCT number
NCT00715364
Sponsor
Stem Cell Therapeutics Corp.
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Stroke
Start date
2009-08-01
Primary completion
2010-06-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.